DeepHealth's Operations Suite™ will enhance WRG's radiology operations through AI-driven applications, improving efficiency and patient care.
Quiver AI Summary
DeepHealth, a subsidiary of RadNet, has announced that Wichita Radiological Group (WRG) will implement its Operations Suite™ to replace its outdated Radiology Information System (RIS). This five-year partnership aims to enhance operational efficiency, care coordination, and patient experience across WRG's multi-site network by utilizing AI-powered applications for workflow automation, advanced analytics, and data interoperability. Kamran Ali, MD, President of WRG, emphasized that the Operations Suite™ will streamline various processes from scheduling to billing, improving patient care through real-time transparency and a personalized approach. The comprehensive platform unifies key operations to enable better resource utilization and reduce staffing pressures, ultimately benefiting patients and staff alike. RadNet’s CEO noted that this collaboration marks a significant step for modernizing radiology practices with advanced technology.
Potential Positives
- DeepHealth’s Operations Suite™ adoption by Wichita Radiological Group highlights the growing trust and reliance on AI-powered health informatics solutions in the medical imaging field.
- The five-year agreement is expected to improve operational efficiency, care coordination, and enhance patient-centered experiences across WRG's multi-site network.
- The modular suite of AI-powered applications promises to streamline workflows, improve staff productivity, and reduce administrative burdens.
- The selection of DeepHealth’s platform by a prominent radiological group reinforces RadNet's position as a key player in modernizing healthcare IT and radiology operations.
Potential Negatives
- There is an overwhelming reliance on forward-looking statements, which carry inherent uncertainties and risks that may mislead stakeholders regarding the company's future performance.
- The press release doesn't provide concrete details or evidence of past successes, which could leave potential clients questioning the reliability and effectiveness of the Operations Suite™.
- There is a risk highlighted concerning the ability to recognize anticipated benefits from the new technology and the potential impact of external factors, which may create skepticism among investors and clients.
FAQ
What is DeepHealth's Operations Suite™?
DeepHealth's Operations Suite™ is an AI-powered platform that unifies healthcare workflows, enhancing operational efficiency in radiology.
How will WRG benefit from using DeepHealth's Operations Suite™?
WRG aims to improve efficiency, collaboration, and care coordination across its multi-site network with the suite's advanced capabilities.
What features does DeepHealth's Operations Suite™ offer?
The suite includes patient engagement tools, workflow automation, advanced analytics, and data interoperability to streamline operations.
How does DeepHealth prioritize patient care?
The platform enhances the patient experience through timely communication, personalized care, and real-time operational transparency.
Where can I learn more about DeepHealth?
Visit deephealth.com for more information and details about their booth at the RSNA 2025 Annual Meeting.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RDNT Insider Trading Activity
$RDNT insiders have traded $RDNT stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $RDNT stock by insiders over the last 6 months:
- RANJAN JAYANATHAN (Chief Information Officer) sold 65,598 shares for an estimated $4,427,865
- MITAL PATEL (EVP of Fin Planning, CAO) has made 0 purchases and 3 sales selling 50,000 shares for an estimated $3,902,254.
- MARK STOLPER (EVP, Chief Financial Officer) sold 35,000 shares for an estimated $2,586,150
- DAVID JEFFREY KATZ (EVP and Chief Legal Officer) has made 0 purchases and 2 sales selling 31,000 shares for an estimated $2,203,430.
- NORMAN R HAMES (Pres and COO-West Operations) has made 0 purchases and 2 sales selling 15,000 shares for an estimated $1,082,900.
- MICHAEL N MURDOCK (EVP, Mergers and Acquisitions) sold 11,132 shares for an estimated $646,212
- CORNELIS WESDORP (Pres & CEO, Digital Health) has made 0 purchases and 3 sales selling 2,500 shares for an estimated $172,530.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RDNT Hedge Fund Activity
We have seen 182 institutional investors add shares of $RDNT stock to their portfolio, and 160 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,924,549 shares (+1312.8%) to their portfolio in Q3 2025, for an estimated $146,669,879
- POLAR CAPITAL HOLDINGS PLC added 832,214 shares (+inf%) to their portfolio in Q3 2025, for an estimated $63,423,028
- VAN BERKOM & ASSOCIATES INC. added 817,808 shares (+14163.6%) to their portfolio in Q3 2025, for an estimated $62,325,147
- ROCKEFELLER CAPITAL MANAGEMENT L.P. added 771,859 shares (+733.7%) to their portfolio in Q3 2025, for an estimated $58,823,374
- FULLER & THALER ASSET MANAGEMENT, INC. added 705,659 shares (+inf%) to their portfolio in Q3 2025, for an estimated $53,778,272
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 646,924 shares (+152.1%) to their portfolio in Q3 2025, for an estimated $49,302,078
- WESTFIELD CAPITAL MANAGEMENT CO LP added 525,820 shares (+inf%) to their portfolio in Q3 2025, for an estimated $40,072,742
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RDNT Analyst Ratings
Wall Street analysts have issued reports on $RDNT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 11/13/2025
- B. Riley Securities issued a "Buy" rating on 06/13/2025
To track analyst ratings and price targets for $RDNT, check out Quiver Quantitative's $RDNT forecast page.
$RDNT Price Targets
Multiple analysts have issued price targets for $RDNT recently. We have seen 4 analysts offer price targets for $RDNT in the last 6 months, with a median target of $80.5.
Here are some recent targets:
- Andrew Mok from Barclays set a target price of $86.0 on 11/13/2025
- David Macdonald from Truist Securities set a target price of $90.0 on 11/12/2025
- John Ransom from Raymond James set a target price of $75.0 on 08/13/2025
- Yuan Zhi from B. Riley Securities set a target price of $69.0 on 06/13/2025
Full Release
SOMERVILLE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- DeepHealth , a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a leader in AI-powered health informatics, today announced Wichita Radiological Group (WRG) has selected DeepHealth’s Operations Suite™ 1 to replace its legacy Radiology Information System (RIS) to advance operations, strengthen care coordination and deliver a more connected, patient-centered imaging experience across its multi-site network.
Leveraging DeepHealth’s Operations Suite™, WRG will implement a modular suite of AI-powered applications to streamline its operational workflows, to enhance productivity and improve staff experience via task automation, advanced analytics and data interoperability. The five-year agreement aims to improve efficiency, boost collaboration and strengthen care coordination.
“DeepHealth’s Operations Suite™ gives us an all-in-one solution to help simplify daily operations, providing real-time transparency and control over operational workflows, which supports our goal to deliver more personalized care for every patient,” said Kamran Ali, MD, President of Wichita Radiological Group. “The solution will transform how we work, improving efficiency from scheduling to billing while ensuring our patients experience more personalized, transparent and timely care at every touchpoint.”
DeepHealth’s Operations Suite™ is an imaging operations platform that unifies scheduling, registration, billing, analytics and patient communication into a seamless, AI-powered platform, streamlining and connecting workflows and empowering imaging teams to work efficiently and prioritize personalized patient care.
The suite of solutions enables workflow automation, such as patient intake and scheduling, while integrating data across systems and delivering role-specific experiences. This has the ability to help practices make better use of resources, streamline operating workflows and ease staffing pressures—ultimately creating a better experience for patients, staff and providers.
Key capabilities include:
- Guided Patient & Staff Experience : A fully digital journey that keeps patients informed and engaged—from scheduling through communicating clinical results. Patients receive clear instructions, updates and reminders—while staff benefit from intelligent prompts and automated workflows intended to reduce administrative work and improve satisfaction.
- Intelligent Operations: Drive streamlined, efficient healthcare IT operations—from scheduling to exam completion—through automated, personalized workflows and AI-powered agents that help balance workloads and optimize resource utilization.
-
Comprehensive, Unified Platform:
Enable scalable, connected healthcare IT operations through a single platform that centralizes workflows, data and performance management across the enterprise for improved visibility and consistency.
“Wichita Radiological Group’s selection of DeepHealth’s Operations Suite™ reflects how forward-thinking practices are preparing for the future of imaging,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health Division. “As more organizations modernize their systems and integrate AI, DeepHealth is becoming a trusted partner in shaping the future of radiology. Our solutions are connected, scalable and designed to help teams focus more on care with less administrative burden.”
WRG’s team of radiologists and support staff provides subspecialty expertise across diagnostic, neuroradiology, pediatric, interventional and women’s imaging. The group reads more than 500,000 studies annually, supporting a Level I trauma center and a VA Medical Center. WRG also owns and operates three outpatient imaging centers, including the area’s only comprehensive women’s imaging facility.
For more information, visit deephealth.com and the DeepHealth booth (#1329 South Hall) at the Radiological Society of North America 2025 Annual Meeting (RSNA 2025), which will take place November 30–December 4 at McCormick Place in Chicago.
About RadNet, Inc.
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 407 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has about 11,000 team members. For more information, visit
radnet.com
.
About DeepHealth
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet’s Digital Health Division. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., CIMAR UK cloud-native healthcare image management solutions, eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, Kheiron, iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, neuro, prostate and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system — DeepHealth OS — that unifies data across clinical and operational workflows and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. For more information, visit
deephealth.com
.
Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the anticipated benefits of the acquisition, the impact of the acquisition on RadNet’s business and future financial and operating results and prospects and the amount and timing of synergies from the acquisition are based on the current estimates, assumptions and projections of RadNet, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes.
These forward‑looking statements are based on our current expectations, estimates, assumptions, and projections and involve uncertainties and risks that are difficult to predict. Actual results may differ materially from those expressed or implied by these forward‑looking statements due to a variety of factors, including, among others: market acceptance and adoption rates for Operations Suite; our ability to successfully develop, manufacture, launch, and scale Operations Suite on anticipated timelines and at expected costs; the performance, reliability, interoperability, and safety of Operations Suite in real‑world conditions; customer acquisition, retention, and usage patterns; our ability to secure and maintain partnerships, suppliers, distribution channels, and key talent; competition, pricing pressure, and technological change; the timing and outcome of regulatory reviews, approvals, certifications, or compliance requirements; intellectual property protection and third‑party claims; cybersecurity, data privacy, and data governance considerations; supply chain constraints and component availability; macroeconomic, geopolitical, public health, and industry‑specific conditions; and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10‑K and Quarterly Reports on Form 10‑Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.
For purposes of this communication, references to our “Operations Suite” include related features, components, modules, optional services, and roadmap items, some of which may not be available in all markets or at all times and remain subject to change without notice.
Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.
Media Contact
Jane Mazur
SVP, Corporate Communications
RadNet
+1 585-355-5978
[email protected]
Mark Stolper
Executive Vice President and Chief Financial Officer
RadNet
+1 310-445-2800
References
1
DeepHealth's Operations Suite™ includes eRAD RIS. Manufactured by eRad and distributed by DeepHealth.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8060446-6151-45b8-9450-d376a2858cbd